On Friday, Takeda Pharmaceutical Co Ltd's (NYSE:TAK) stock wobbled after touching as low as $14.53 during the premarket session, before bouncing back to about $15.47 at last check Friday.
On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Dawnzera (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.
Investors should note that Takeda also has a hereditary angioedema prevention drug, Takhzyro (lanadelumab), that gained FDA approval in 2018 and expanded use approval for pediatrics in 2023.
Also Read: FDA Approves KalVista’s Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease
Reuters, citing a TD Cowen analyst, noted that patients not doing well on existing therapies can switch to Dawnzera, which is more effective.
Takhzyro, given every two weeks, showed an average of 87% fewer attacks compared to a placebo over 6.5 months in a separate study involving adult and adolescent patients.
Reuters reported Dawnzera will be available in the United States in the coming days with a list price of $57,462 per dose and estimated peak annual sales of Ionis’ drug to be $509 million by 2032.
During the second quarter of 2025, Takhzyro sales rose by 3.7% to 55.1 billion yen.
How To Buy TAK Stock
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Takeda Pharmaceutical's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Price Action: TAK stock is up 1.01% at $15.47 at the last check on Friday.
Read Next:
Image: Shutterstock
